Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 8;10(9):1498.
doi: 10.3390/vaccines10091498.

Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population

Protim Sarker  1 , Evana Akhtar  1 , Rakib Ullah Kuddusi  1 , Mohammed Mamun Alam  1 , Md Ahsanul Haq  1 , Md Biplob Hosen  1 , Bikash Chandra Chanda  2 , Farjana Haque  1 , Muntasir Alam  1 , Abdur Razzaque  3 , Mustafizur Rahman  1 , Faruque Ahmed  4 , Md Golam Kibria  4 , Mohammed Zahirul Islam  5 , Shehlina Ahmed  6 , Rubhana Raqib  1
Affiliations

Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population

Protim Sarker et al. Vaccines (Basel). .

Abstract

Background: The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination.

Methods: We studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population (n = 1780).

Results: mRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (BMEM), total CD8+T, CD4+ central memory (CD4+CM) and T-regulatory (TREG) cells were more numerous in AstraZeneca vaccine recipients compared to other vaccine recipients. Plasmablasts, B-regulatory (BREG) and CD4+ effector (CD4+EFF) cells were more numerous in mRNA vaccine recipients.

Conclusions: mRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.

Keywords: B cell; SARS-CoV-2; T cell; cellular immunity; humoral immunity; neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
SARS-CoV-2 S-protein-specific antibody levels in study participants after two doses of vaccination. (A) Comparison of antibody levels between different SARS-CoV-2 vaccines; (B) differences in antibody titer between RT-PCR positive and negative participants; (C) comparison of antibody levels between participants positive and negative for SARS-CoV-2 N-protein-specific antibody. A 2-way ANCOVA model was used to estimate the p-value, and the model was adjusted for age, sex, income and BMI.
Figure 2
Figure 2
Neutralizing antibody titers in different vaccine groups. A 2-way ANCOVA was used to estimate the p-value, and the model was adjusted for age, sex, income and BMI.
Figure 3
Figure 3
Proportion of immune cells in different vaccine groups. (A) Proportion of B cell subtypes; (B) Proportion of T cell subtypes. A 2-way ANCOVA was used to estimate the p-value, and the model was adjusted for age, sex, income and BMI. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 4
Figure 4
IFN-γ-secreting T cells in different vaccine groups. A 2-way ANCOVA was used to estimate the p-value, and the model was adjusted for age, sex, income and BMI.
See this image and copyright information in PMC

References

    1. Poland G.A., Ovsyannikova I.G., Kennedy R.B. The need for broadly protective COVID-19 vaccines: Beyond S-only approaches. Vaccine. 2021;39:4239–4241. doi: 10.1016/j.vaccine.2021.06.028. - DOI - PMC - PubMed
    1. Addetia A., Crawford K.H.D., Dingens A., Zhu H., Roychoudhury P., Huang M.L., Jerome K.R., Bloom J.D., Greninger A.L. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J. Clin. Microbiol. 2020;58:e02107-20. doi: 10.1128/JCM.02107-20. - DOI - PMC - PubMed
    1. Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8. - DOI - PubMed
    1. Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063. - DOI - PMC - PubMed
    1. Kojima N., Klausner J.D. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect. Dis. 2022;22:12–14. doi: 10.1016/S1473-3099(21)00676-9. - DOI - PMC - PubMed